Elicio Therapeutics, Inc. Investigation

Company: Elicio Therapeutics, Inc.

Ticker: (NASDAQ) ELTX

See If You Qualify For Monetary Reward

Join the Elicio Therapeutics, Inc. Class Action Lawsuit

Investigation Details

On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed. The Q1 2026 filing showed the Company generated no product revenue while reporting increased research and development expenses tied to the AMPLIFY-7P program. The Company's cash position funded operations centered on ELI-002 7P as its lead pipeline candidate. On June 15, the 144-patient Phase 2 trial missed its pre-specified primary endpoint. Days before the trial data became public, B. Riley Securities had issued a Buy rating with a $27 price target on June 10-11. The stock closed at only $4.08 after the Phase 2 miss was disclosed on June 15.

Frequently Asked Questions

How do I join the lawsuit against Elicio Therapeutics, Inc. (NASDAQ: ELTX)?

Investors who purchased shares of Elicio Therapeutics, Inc. (NASDAQ: ELTX) during the class period (June 16, 2021 - June 16, 2026) can join by submitting their transaction details through this case page.

Ensure your purchase falls within the class period
Provide basic transaction and loss details
Submit your information before the deadline

The lead plaintiff deadline for this case is To be determined, so investors should act quickly to protect their rights.

Who is eligible for the Elicio Therapeutics, Inc. lawsuit?

Anyone who bought shares of Elicio Therapeutics, Inc. (NASDAQ: ELTX) during June 16, 2021 - June 16, 2026 and suffered financial losses may qualify.

What is the lead plaintiff deadline to join the Elicio Therapeutics, Inc. case?

The lead plaintiff deadline for the Elicio Therapeutics, Inc. lawsuit is To be determined. Investors should act quickly to avoid missing this deadline.

What is the class period for Elicio Therapeutics, Inc.?

The class period for Elicio Therapeutics, Inc. (NASDAQ: ELTX) is June 16, 2021 - June 16, 2026, during which investors may have been affected by alleged misconduct.

Can I still join the Elicio Therapeutics, Inc. lawsuit if I sold my shares?

Yes. Investors who purchased Elicio Therapeutics, Inc. shares during June 16, 2021 - June 16, 2026 may still qualify, even if they sold their shares later.

How much compensation can I receive from the Elicio Therapeutics, Inc. lawsuit?

Compensation depends on the total losses and the final settlement. Eligible investors in the Elicio Therapeutics, Inc. case may receive a portion of the recovery.

Do I need to pay to participate in the Elicio Therapeutics, Inc. case?

No, most securities fraud cases involving Elicio Therapeutics, Inc. operate on a contingency basis, meaning there are no upfront costs unless there is a recovery.

Will I need to appear in court for the Elicio Therapeutics, Inc. lawsuit?

In most cases, investors do not need to appear in court. The legal team manages the Elicio Therapeutics, Inc. case on behalf of participants.

What documents are required for the Elicio Therapeutics, Inc. lawsuit?

To participate in the Elicio Therapeutics, Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.

What happens after I submit my trade information for Elicio Therapeutics, Inc.?

After submission, your details for the Elicio Therapeutics, Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.

Is this legal advice for the Elicio Therapeutics, Inc. lawsuit?

No, this page provides information about the Elicio Therapeutics, Inc. case and does not constitute legal advice or create an attorney-client relationship.

Why should I act quickly on the Elicio Therapeutics, Inc. case?

The lead plaintiff deadline for the Elicio Therapeutics, Inc. lawsuit is To be determined. If you are an investor, you may have the opportunity to seek appointment as lead plaintiff or remain an absent class member.